Trial Profile
Clinical Study on the Safety and Efficacy of Commercialized CD19CART Cells in the Treatment of Refractory, Invasive Non-Hodgkin's Lymphoma (NHL)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Feb 2018
Price :
$35
*
At a glance
- Drugs Anti cd19 CAR T cell therapy Innovative Cellular Therapeutics (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 27 Feb 2018 New trial record